Matthew Pauls
CIK 1573429 · CHIEF EXECUTIVE OFFICER · last filed 2026-07-07
Matthew Pauls is a CHIEF EXECUTIVE OFFICER who has filed 49 SEC Form 4 insider transactions across 7 companies since 2013. The most recent filing shows the insider sold $20.6K of PTHS on Jul 7, 2026. Across all open-market trades the lifetime net is −$798.3K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.73M
7
49
-$798.3K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PTHS | Director | 14,364 | $27.77 | $398.9K | -$37.0K | 5 | 2026-07-07 |
| PVLA | Director | — | $142.84 | — | $0 | 1 | 2026-07-01 |
| SOLENO THERAPEUTICS INC (SLNO) Delisted | Director | 0 | $53.01 | $0 | -$424.8K | 5 | 2026-05-18 |
| SVRA | CHIEF EXECUTIVE OFFICER | 1,188,050 | $5.33 | $6.33M | -$336.5K | 21 | 2025-12-16 |
| Strongbridge Biopharma plc (SBBP) Delisted | President & CEO | 72,608 | $2.00 | $145.2K | $0 | 3 | 2019-02-22 |
| MSTX | Director | — | $8.58 | — | $0 | 3 | 2017-01-23 |
| INSM | Chief Commercial Officer | — | $104.13 | — | $0 | 3 | 2014-01-14 |
Recent Filings
49 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-07 | PTHS | Sell (S) | −786 | -$20.6K | EDGAR |
| 2026-07-01 | PVLA | Grant (A) | — | $0 | EDGAR |
| 2026-05-18 | SOLENO THERAPEUTICS INC (SLNO) Delisted | Disp (D) | −10,491 | $0 | EDGAR |
| 2026-04-06 | PTHS | Sell (S) | −786 | -$16.4K | EDGAR |
| 2026-04-01 | PTHS | Grant (A) | +25,478 | $0 | EDGAR |
| 2025-12-16 | SVRA | Mixed | −324,700 | -$1.35M | EDGAR |
| 2025-12-12 | PTHS | Mixed | +1,074 | $0 | EDGAR |
| 2025-12-11 | SVRA | Gift (G) | −23,629 | $0 | EDGAR |
| 2025-07-07 | PTHS | Grant (A) | — | $0 | EDGAR |
| 2025-06-09 | SOLENO THERAPEUTICS INC (SLNO) Delisted | Grant (A) | +3,991 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.